Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Research has examined its anxiolytic properties in animal models, GABAergic modulation, and cognitive enhancement effects.
Structure and Development
Selank is based on the tetrapeptide tuftsin (Thr-Lys-Pro-Arg) extended with Glu-Asp-Gly to improve metabolic stability. This sequence engineering reflects a design strategy of taking an endogenous bioactive peptide and extending it to prevent rapid enzymatic degradation while preserving or enhancing its biological effects.
Anxiolytic Mechanism Research
Animal model studies have demonstrated anxiolytic effects comparable to benzodiazepines in elevated plus maze and other standard anxiety behavioral paradigms, but notably without the sedative, amnestic, or muscle-relaxant effects associated with benzodiazepine use. Research suggests the mechanism involves modulation of GABAergic transmission and potentially serotonin systems.
BDNF Modulation
Like Semax, Selank has been studied for its effects on neurotrophic factor expression. Research has reported upregulation of BDNF in brain regions including the hippocampus and frontal cortex, potentially contributing to both cognitive and anxiolytic effects through neuroplasticity mechanisms.
Clinical Applications in Russia
Selank is approved in Russia for the treatment of generalized anxiety disorder and neurasthenia. It is administered intranasally. The evidence base supporting its clinical use in Russia includes a number of controlled trials, though most of this research has not been independently replicated in Western clinical research settings.
Research Disclaimer: This article is for educational purposes only and does not constitute medical advice.